FDA Debunks Pfizer’s Claim: ‘No Evidence’ that Retaking Paxlovid Pill Stops Recurring Covid-19 Symptoms

FDA Debunks Pfizer’s Claim: ‘No Evidence’ that Retaking Paxlovid Pill Stops Recurring Covid-19 Symptoms


Picture Alliance via Getty Images

U.S. Food and Drug Administration said on Wednesday that using Pfizer’s Paxlovid pill has “no evidence of benefit at this time for a longer course of treatment” in patients with recurrent Covid-19 symptoms, contradicting Pfizer’s CEO Albert Bourla’s comments.

As the Gateway Pundit previously reported, there are more and more reports of patients who were taking Pfizer’s antiviral pill experiencing a second round of Covid-19 shortly after recovering and doctors were baffled.

Trending: State Farm Donating Transgender Books for Kindergarteners to Schools in Florida, Whistleblower Reveals

In cases where virus levels rebound, “then you give a second course, like you do with antibiotics, and that’s it,” Pfizer CEO Albert Bourla told Bloomberg on Tuesday.

The FDA released a statement on Wednesday debunking Pfizer’s chief executive

Continue reading

You Might Like

 

Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Thanks for sharing!
Send this to a friend